AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25275672 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100 mg, oral, twice daily, titrated over 2 weeks)
Number of subjects: 52
Study 25275672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22527079 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 μg/kg/min continuous infusion for 72 hours)
Number of subjects: 63
Study 22527079 — intervention group
Group type: COMPARATOR
Intervention: Standard post‐CPB inotrope infusion
Number of subjects: 63
Study 22527079 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 63
Study 20008998 — intervention group
Group type: COMPARATOR
Intervention: Embryonic dopamine cell implantation
Number of subjects: 33
Study 18525288 — intervention group
Group type: EXPERIMENTAL
Intervention: Music Therapy (MT)
Number of subjects: 59
Study 18525288 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational support or entertainment activities)
Number of subjects: 59
Study 16135979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone Seal
Number of subjects: 112
Study 16135979 — intervention group
Group type: COMPARATOR
Intervention: Collagen fleece (Lyostypt)
Number of subjects: 112
Study 12746365 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A intervention (3 clinical problems: cardiovascular topics, upper and lower abdominal complaints)
Number of subjects: 174
Study 12746365 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B intervention (3 clinical problems: chronic obstructive pulmonary disease, asthma, general complaints, degenerative joint complaints)
Number of subjects: 174
Study 12746365 — intervention group
Group type: COMPARATOR
Intervention: Arm A control (for problems allocated to arm B)
Number of subjects: 174
Study 12746365 — intervention group
Group type: COMPARATOR
Intervention: Arm B control (for problems allocated to arm A)
Number of subjects: 174
Study 10373872 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire administered on the second postnatal day
Number of subjects: 615
Study 7718101 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilled cabbage leaves
Number of subjects: 34
Study 7718101 — intervention group
Group type: COMPARATOR
Intervention: Chilled gelpaks
Number of subjects: 34
Study 2201759 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival irrigation with 0.12% CHX and daily marginal irrigation with 0.04% CHX
Number of subjects: 60
Study 2201759 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival irrigation with 0.12% CHX and daily marginal irrigation with water
Number of subjects: 60
Study 2201759 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival and daily marginal irrigation with water
Number of subjects: 60
Study 2201759 — intervention group
Group type: COMPARATOR
Intervention: Non‐irrigation (control)
Number of subjects: 60
Study 7024807 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 41
Study 31713774 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) treatment at 50 to 200 nmol/L
Number of subjects: 7
Study 31713774 — intervention group
Group type: COMPARATOR
Intervention: LPS treatment (only LPS)
Number of subjects: 7
Study 31713774 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) treatment with LPS (LS50 to LS200)
Number of subjects: 7
Study 31713774 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) treatment at 50 to 100 nmol/L
Number of subjects: 7
Study 31713774 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium (Se) treatment
Number of subjects: 7
Study 30203546 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation exercises (3 days per week for 8 weeks)
Number of subjects: 44
Study 30203546 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 44
Study 28407007 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily (Arm A)
Number of subjects: 303
Study 28407007 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, each twice daily) plus polaprezinc 150 mg twice daily (Arm B)
Number of subjects: 303
Study 28407007 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy alone (Arm C)
Number of subjects: 303
Study 28407007 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 303
Study 28407007 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (Triple therapy plus polaprezinc 150 mg)
Number of subjects: 303
Study 26286610 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% Mometasone Furoate Cream (MF) in combination with LA-Cer moisturizer
Number of subjects: 106
Study 26286610 — intervention group
Group type: COMPARATOR
Intervention: 0.1% Mometasone Furoate Cream (MF)
Number of subjects: 106
Study 26286610 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-Cer-MF
Number of subjects: 106
Study 26286610 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-Cer-group (T2)
Number of subjects: 106
Study 24220723 — intervention group
Group type: EXPERIMENTAL
Intervention: The Integrated Skin Exam film
Number of subjects: 8
Study 20923378 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype colonoscope with graded flaccidity
Number of subjects: 400
Study 20923378 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype colonoscope with ungraded flaccidity
Number of subjects: 400
Study 20923378 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscope
Number of subjects: 400
Study 20923378 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype group (both graded and ungraded)
Number of subjects: 400
Study 20923378 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 400
Study 20923378 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype group
Number of subjects: 400
Study 20015319 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alpha (activated) (DAA)
Number of subjects: 3348
Study 20015319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3348
Study 17408389 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy silicone oil (Densiron(R))
Number of subjects: 700
Study 17408389 — intervention group
Group type: COMPARATOR
Intervention: Standard silicone oil (1000 cSt or 5000 cSt)
Number of subjects: 700
Study 15103194 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal electromyography (EMG)
Number of subjects: 35
Study 11409683 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone mouthguard
Number of subjects: 52
Study 11409683 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic mouthguard
Number of subjects: 52
Study 11094038 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of prostacyclin in 15 patients with PPH and 3 with sPAH.
Number of subjects: 105
Study 11094038 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects).
Number of subjects: 105
Study 8659199 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg/day
Number of subjects: 90
Study 8659199 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol 200 mg/day
Number of subjects: 90
Study 8659199 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 80 mg/day
Number of subjects: 90
Study 8659199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 1644341 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal oxygen supplementation (2 l/min)
Number of subjects: 66
Study 1644341 — intervention group
Group type: COMPARATOR
Intervention: Minimal midazolam sedation alone (Control)
Number of subjects: 66
Study 6240785 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamphenicol (2.5 g perorally)
Number of subjects: 370
Study 6240785 — intervention group
Group type: COMPARATOR
Intervention: Aqueous procaine penicillin G (4.8 X 10(6) units im) plus probenecid (1 g perorally)
Number of subjects: 370
Study 6240785 — intervention group
Group type: COMPARATOR
Intervention: Spectinomycin (2 g im)
Number of subjects: 370
Study 31439584 — intervention group
Group type: EXPERIMENTAL
Intervention: osimertinib
Number of subjects: 556
Study 31439584 — intervention group
Group type: COMPARATOR
Intervention: Comparator EGFR-TKI
Number of subjects: 556
Study 29384839 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-thumbs-fist technique (nTTT)
Number of subjects: 63
Study 29384839 — intervention group
Group type: COMPARATOR
Intervention: 2-finger technique (TFT)
Number of subjects: 63
Study 29384839 — intervention group
Group type: COMPARATOR
Intervention: 2-thumb-encircling hands technique (TTEHT)
Number of subjects: 63
Study 26813849 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 once-daily pills after each donation (19 mg of iron)
Number of subjects: 692
Study 26813849 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 once-daily pills after each donation (38 mg of iron)
Number of subjects: 692
Study 26813849 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron status information letter after each donation
Number of subjects: 692
Study 26813849 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 692
Study 26813849 — intervention group
Group type: COMPARATOR
Intervention: No information letter
Number of subjects: 692
Study 25664051 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D oral supplementation (45000 IU/week for 2 months and a single 45000 IU in the last month)
Number of subjects: 200
Study 25664051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 23130536 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robot‐assisted lingual tonsillectomy with uvulopalatopharyngoplasty
Number of subjects: 20
Study 20125103 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich breakfast (PR) - 48g protein
Number of subjects: 13
Study 20125103 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-protein breakfast (PN) - 18g protein
Number of subjects: 13
Study 20125103 — intervention group
Group type: COMPARATOR
Intervention: Breakfast skipping (BS)
Number of subjects: 13
Study 18410902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous busulfan 130 mg/m(2) once daily x 4 days and fludarabine 40 mg/m(2) daily x 4 days
Number of subjects: 10
Study 18410902 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 10
Study 15741746 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 24
Study 15741746 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 24
Study 12429757 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Sequential transection of the triangular fibrocartilage complex and the interosseous membrane
Number of subjects: 12
Study 12429757 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Sequential transection of the interosseous membrane and the triangular fibrocartilage complex
Number of subjects: 12
Study 12429757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups: Transection of both the triangular fibrocartilage complex and the interosseous membrane
Number of subjects: 12
Study 12429757 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after load removal
Number of subjects: 12
Study 10339471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic inhalations with aerosolized amphotericin B (aeroAmB) at a dose of 10 mg twice daily
Number of subjects: 382
Study 10339471 — intervention group
Group type: COMPARATOR
Intervention: No inhalation prophylaxis
Number of subjects: 382
Study 10339471 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic inhalations with aerosolized amphotericin B (aeroAmB)
Number of subjects: 382
Study 7499945 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone nasal spray (Beconase) applied to one nostril for six weeks
Number of subjects: 29
Study 7499945 — intervention group
Group type: COMPARATOR
Intervention: Control nostril (untreated)
Number of subjects: 29
Study 1959515 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutch dietary guidelines diet (G)
Number of subjects: 12
Study 31099485 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 49
Study 31099485 — intervention group
Group type: EXPERIMENTAL
Intervention: Active disease
Number of subjects: 49
Study 31099485 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX therapy
Number of subjects: 49
Study 31099485 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX cumulative dose
Number of subjects: 49
Study 31099485 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX treatment duration
Number of subjects: 49
Study 31099485 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity
Number of subjects: 49
Study 31099485 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 49
Study 29389510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention integrating motivational interviewing, active learning, and applied problem solving to increase whole plant food intake
Number of subjects: 136
Study 29389510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 136
Study 29389510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention
Number of subjects: 136
Study 26291745 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior left atrial wall plication (T‐plasty)
Number of subjects: 60
Study 26291745 — intervention group
Group type: COMPARATOR
Intervention: No left atrial size reduction (Control Group)
Number of subjects: 60
Study 25431865 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DNR/FLAG (liposomal daunorubicin, fludarabine, cytarabine, G-CSF)
Number of subjects: 155
Study 25431865 — intervention group
Group type: COMPARATOR
Intervention: FLAG only
Number of subjects: 155
Study 25431865 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DNR/FLAG
Number of subjects: 155
Study 22633893 — intervention group
Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 60
Study 22633893 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 60
Study 20332741 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 3350
Study 17277603 — intervention group
Group type: EXPERIMENTAL
Intervention: Action Schools! BC (AS! BC) intervention
Number of subjects: 287
Study 17277603 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (UP)
Number of subjects: 287
Study 15676064 — intervention group
Group type: COMPARATOR
Intervention: Full vacuum suction drainage (pressure = 700 g/m2)
Number of subjects: 85
Study 15676064 — intervention group
Group type: EXPERIMENTAL
Intervention: Half vacuum suction drainage (pressure = 350 g/m2)
Number of subjects: 85
Study 12018455 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled Longo procedure
Number of subjects: 80
Study 12018455 — intervention group
Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy
Number of subjects: 80
Study 12018455 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 80
Study 9988403 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-dimensional partial zona dissection
Number of subjects: 340
Study 9988403 — intervention group
Group type: COMPARATOR
Intervention: Conventional partial zona dissection
Number of subjects: 340
Study 7752591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/day
Number of subjects: 94
Study 7752591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 2098653 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/daily)
Number of subjects: 17
Study 2098653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6986242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 41
Study 6986242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 tablets twice daily)
Number of subjects: 41
Study 30793177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3 (250,000 IU single dose followed by 50,000 IU every other week)
Number of subjects: 91
Study 30793177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identically matched placebo pill)
Number of subjects: 91
Study 30793177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 3
Number of subjects: 91
Study 30793177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 27632839 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance Training with STARS (BTS)
Number of subjects: 24
Study 27632839 — intervention group
Group type: COMPARATOR
Intervention: Balance Training (BT)
Number of subjects: 24
Study 26159020 — intervention group
Group type: EXPERIMENTAL
Intervention: CHSQABC + routine Western medicine treatment (Xinyue Capsule: 2 pills, 3 times/day; Compound Chuanxiong Capsule: 2 pills, 3 times/day for half a year)
Number of subjects: 281
Study 26159020 — intervention group
Group type: COMPARATOR
Intervention: Routine Western medicine treatment (control group)
Number of subjects: 281
Study 26159020 — intervention group
Group type: EXPERIMENTAL
Intervention: CHSQABC + routine Western medicine treatment
Number of subjects: 281
Study 24354904 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 16
Study 24354904 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 16
Study 24354904 — intervention group
Group type: EXPERIMENTAL
Intervention: Left lateral decubitus position
Number of subjects: 16
Study 24354904 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral decubitus position
Number of subjects: 16
Study 21995296 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem
Number of subjects: 90
Study 21995296 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC
Number of subjects: 90
Study 21995296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cement-Post
Number of subjects: 90
Study 21995296 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxCem
Number of subjects: 90
Study 21995296 — intervention group
Group type: COMPARATOR
Intervention: Post configurations (parallel‐sided and serrated vs tapered and smooth)
Number of subjects: 90
Study 20415263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon (exact dosage not specified)
Number of subjects: 0
Study 15899447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric Tecnis IOL (Pfizer/Pharmacia Tecnis Z9000)
Number of subjects: 60
Study 15899447 — intervention group
Group type: COMPARATOR
Intervention: Conventional AcrySof IOL (Alcon AcrySof SA60AT)
Number of subjects: 60
Study 15899447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric Tecnis IOL
Number of subjects: 60
Study 12673423 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-y esophagojejunostomy (r-y)
Number of subjects: 0
Study 12673423 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-y with pouch (p-y)
Number of subjects: 0
Study 12673423 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal interposition with pouch (p-i)
Number of subjects: 0
Study 12673423 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11021706 — intervention group
Group type: EXPERIMENTAL
Intervention: Labial flap approach
Number of subjects: 10
Study 11021706 — intervention group
Group type: COMPARATOR
Intervention: Crestal incision approach
Number of subjects: 10
Study 11021706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 10
Study 8927663 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 54
Study 8927663 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 54
Study 8927663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 1800749 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips 5306B electronic manometer
Number of subjects: 0
Study 1800749 — intervention group
Group type: COMPARATOR
Intervention: Hawksley random zero mercury manometer
Number of subjects: 0
Study 6356326 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal hormones (VIP, motilin, enteroglucagon)
Number of subjects: 0
Study 6356326 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon, enkephalins, somatostatin
Number of subjects: 0
Study 31727580 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-guided empirical tuberculosis treatment
Number of subjects: 3022
Study 31727580 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 3022
Study 31240811 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of at-home cessation support
Number of subjects: 404
Study 31240811 — intervention group
Group type: COMPARATOR
Intervention: NICE PH48 care as usual
Number of subjects: 404
Study 28452870 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to MT protocol activation
Number of subjects: 680
Study 28452870 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to delivery of first cooler
Number of subjects: 680
Study 28452870 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased time to MT activation
Number of subjects: 680
Study 28452870 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased time to arrival of first cooler
Number of subjects: 680
Study 28452870 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to achieving hemostasis
Number of subjects: 680
Study 25273547 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei subsp. paracasei L. casei W8® (1010 cfu daily) for four weeks
Number of subjects: 64
Study 23783097 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA (5 mmol/L)
Number of subjects: 12
Study 23783097 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA (15 mmol/L)
Number of subjects: 12
Study 23783097 — intervention group
Group type: EXPERIMENTAL
Intervention: CDCA (5 or 15 mmol/L)
Number of subjects: 12
Study 23783097 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 23783097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oleate with 5 mmol/L CDCA
Number of subjects: 12
Study 21856968 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher responsivity education intervention
Number of subjects: 330
Study 21856968 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control condition
Number of subjects: 330
Study 19173181 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y‐DOTATATE (7.4 GBq/m(2) cumulative dose)
Number of subjects: 62